These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36172110)

  • 21. The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR
    Shao B; Li H; Zhang J; Liu X; Song G; Jiang H; Yan Y; Wang H; Wang J; Di L
    Ann Transl Med; 2022 Aug; 10(16):901. PubMed ID: 36111005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
    Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
    Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
    Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2- patients with metastatic breast cancer.
    Li J; Zhang X; Yang C; Lv Y; Yang H; Kong X; Han M; Wang Z; Ma J; Han J; Liu Y
    Medicine (Baltimore); 2021 Nov; 100(44):e27710. PubMed ID: 34871262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.
    Kolarov Bjelobrk I; Radic J; Trifunovic J; Pesic J; Vidovic V; Vranjkovic B; Petrovic N; Andrejic Visnjic B
    J Chemother; 2022 Jul; 34(4):264-271. PubMed ID: 34844517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China.
    Chen Z; Ouyang Q; Wang Y; Wang J; Wang H; Wu X; Zhang P; Huang J; Zheng Y; Cao W; Shao X; Xie N; Tian C; Liang H; Wang C; Zhang Y; Ren D; Wang X
    Front Oncol; 2022; 12():829693. PubMed ID: 35311126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.
    Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Wu EQ
    Exp Hematol Oncol; 2015; 4():31. PubMed ID: 26693096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer.
    Surmeli ZG; Varol U; Cakar B; Degirmenci M; Arslan C; Piskin GD; Zengel B; Karaca B; Sanli UA; Uslu R
    Oncol Lett; 2015 Oct; 10(4):2598-2602. PubMed ID: 26622896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
    Van Raemdonck E; Floris G; Berteloot P; Laenen A; Vergote I; Wildiers H; Punie K; Neven P
    Breast Cancer Res Treat; 2021 Jan; 185(1):183-194. PubMed ID: 32980945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
    Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
    Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.
    Rak Tkaczuk KH
    Breast Cancer (Auckl); 2011 Jan; 5():1-14. PubMed ID: 21494397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
    Xie Y; Zhao Y; Gong C; Chen Z; Zhang Y; Zhao Y; Yuan P; Hu S; Li Y; Hu X; Zhang J; Wang L; Wang B
    Sci Rep; 2019 Feb; 9(1):1710. PubMed ID: 30737426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
    Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
    Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
    Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Lahdenperä O; Kosonen S; Villman K; Nyandoto P; Nilsson G; Poikonen-Saksela P; Kataja V; Junnila J; Bono P; Lindman H
    JAMA Oncol; 2017 Jun; 3(6):793-800. PubMed ID: 28253390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
    Kim HK; Lee SH; Kim YJ; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Ahn JS; Im YH; Yu JH; Park YH
    BMC Cancer; 2019 Jan; 19(1):84. PubMed ID: 30654765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population.
    Babyshkina N; Malinovskaya E; Patalyak S; Bragina O; Tarabanovskaya N; Doroshenko A; Slonimskaya E; Perelmuter V; Cherdyntseva N
    Med Oncol; 2014 Sep; 31(9):165. PubMed ID: 25139196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance.
    Križić M; Popović M; Silovski T; Grbin D; Dedić Plavetić N
    Drugs Real World Outcomes; 2024 Jun; ():. PubMed ID: 38879832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.